Pfizer Inc. (NYSE: PFE) is scheduled to report fourth quarter 2019 earnings results on Tuesday, January 28, before the market opens. Both revenue and earnings are expected to be lower than the numbers reported in the year-ago period.
Analysts have forecast earnings of $0.57 per share which is lower than $0.64 reported last year. Revenues are expected to drop 9% to $12.61 billion.
The company’s key products Ibrance, Xeljanz, Eliquis and Inlyta can be expected to continue their momentum in the fourth quarter boosting growth in the Biopharma segment. However, it remains to be seen if the weakness in Enbrel and Prevnar 13 will continue in the to-be-reported quarter.
The Upjohn division has seen weak revenues due to volume declines and generic competition for some of its products. It remains to be seen if this trend carries on into the fourth quarter as well.
Pfizer has received several FDA approvals during the quarter including the approval of biosimilar ABRILADA for the treatment of multiple inflammatory conditions as well as XELJANZ XR extended release tablets for ulcerative colitis. Updates on this area will be worth watching.
Also read: Pfizer Q3 2019 Earnings Conference Call Transcript
Another topic to note will be updates on the combination of Mylan NV (NASDAQ: MYL) and Upjohn, which is anticipated to be completed in mid-2020.
In the third quarter of 2019, Pfizer topped market expectations despite posting declines in the top and bottom line numbers. Revenues fell 5% to $12.7 billion while adjusted EPS dropped 2% to $0.75. Revenues in the Biopharma segment increased 7% while the Upjohn and Consumer Healthcare divisions saw sales declines of 28% and 55% respectively.
For the full year of 2019, Pfizer has guided for revenues of $51.2 billion to $52.2 billion and adjusted EPS of $2.94 to $3.00.
Shares of Pfizer have declined 5% in the past one year. The stock has an average price target of $41.26.
Most Popular
Stitch Fix (SFIX) Stock: Will the innovative biz model survive virus-led slump?
The business world is still struggling to come out of the virus-induced slowdown, but it seems almost every retail segment benefited from the pandemic at some point. The vaccination drive
General Mills (GIS): Three factors that are expected to help drive growth for the food company going forward
Shares of General Mills Inc. (NYSE: GIS) were up 3.2% on Wednesday after the company delivered better-than-expected results for the first quarter of 2022. Net sales rose 4% year-over-year to
IPO Alert: Allvue Systems sets IPO terms, to raise around $290 million
It is estimated that the alternative investments industry has expanded at a compound annual rate of 10.2% over the past ten years and had $11 trillion in assets under management
